Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atogepant in chronic or episodic migraine
NCT04686136Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2021
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 3 trial of atogepant in migraine, sponsored by AbbVie Inc.. Started Feb 2021; status: completed.
02
Drugs
atogepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT04686136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04686136.